These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21658633)

  • 41. New antimicrobial strategies in cystic fibrosis.
    van Westreenen M; Tiddens HA
    Paediatr Drugs; 2010 Dec; 12(6):343-52. PubMed ID: 21028914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cystic fibrosis microbiome in an ecological perspective and its impact in antibiotic therapy.
    Magalhães AP; Azevedo NF; Pereira MO; Lopes SP
    Appl Microbiol Biotechnol; 2016 Feb; 100(3):1163-1181. PubMed ID: 26637419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increase in interleukin-8 production from circulating neutrophils upon antibiotic therapy in cystic fibrosis patients.
    Montemurro P; Mariggiò MA; Barbuti G; Cassano A; Vincenti A; Serio G; Guerra L; Diana A; Santostasi T; Polizzi A; Fumarulo R; Casavola V; Manca A; Conese M
    J Cyst Fibros; 2012 Dec; 11(6):518-24. PubMed ID: 22608703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microbiome in cystic fibrosis: Shaping polymicrobial interactions for advances in antibiotic therapy.
    Lopes SP; Azevedo NF; Pereira MO
    Crit Rev Microbiol; 2015; 41(3):353-65. PubMed ID: 24645634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Azithromycin therapy in cystic fibrosis].
    Máiz Carro L; Cantón Moreno R
    Med Clin (Barc); 2004 Mar; 122(8):311-6. PubMed ID: 15030744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations.
    Scott LK; Toner R
    Lung; 2017 Aug; 195(4):397-401. PubMed ID: 28623538
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.
    Zemanick ET; Harris JK; Conway S; Konstan MW; Marshall B; Quittner AL; Retsch-Bogart G; Saiman L; Accurso FJ
    J Cyst Fibros; 2010 Jan; 9(1):1-16. PubMed ID: 19833563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models.
    Hittinger M; Juntke J; Kletting S; Schneider-Daum N; de Souza Carvalho C; Lehr CM
    Adv Drug Deliv Rev; 2015 May; 85():44-56. PubMed ID: 25453270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Azithromycin use in patients with cystic fibrosis.
    Principi N; Blasi F; Esposito S
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1071-9. PubMed ID: 25686729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Year in Review IV: Interstitial lung disease, cystic fibrosis, pulmonary infections, and mycobacterial disease.
    Tino G
    Proc Am Thorac Soc; 2006 Nov; 3(8):650-3. PubMed ID: 17065369
    [No Abstract]   [Full Text] [Related]  

  • 51. Host-pathogen interplay in the respiratory environment of cystic fibrosis.
    Yonker LM; Cigana C; Hurley BP; Bragonzi A
    J Cyst Fibros; 2015 Jul; 14(4):431-439. PubMed ID: 25800687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus.
    Döring G; Hoiby N;
    J Cyst Fibros; 2004 Jun; 3(2):67-91. PubMed ID: 15463891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cystic fibrosis therapy: a community ecology perspective.
    Conrad D; Haynes M; Salamon P; Rainey PB; Youle M; Rohwer F
    Am J Respir Cell Mol Biol; 2013 Feb; 48(2):150-6. PubMed ID: 23103995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Basic therapies in cystic fibrosis. Does standard therapy work?
    Marshall BC; Samuelson WM
    Clin Chest Med; 1998 Sep; 19(3):487-504, vi. PubMed ID: 9759551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Culture-based diagnostic microbiology in cystic fibrosis: can we simplify the complexity?
    Burns JL; Rolain JM
    J Cyst Fibros; 2014 Jan; 13(1):1-9. PubMed ID: 24094376
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibiotic and anti-inflammatory therapies for cystic fibrosis.
    Chmiel JF; Konstan MW; Elborn JS
    Cold Spring Harb Perspect Med; 2013 Oct; 3(10):a009779. PubMed ID: 23880054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. From pipeline to patient: new developments in cystic fibrosis therapeutics.
    Prayle AP; Smyth AR
    Expert Opin Pharmacother; 2013 Feb; 14(3):323-9. PubMed ID: 23374028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Episodic oral antibiotic use in CF: Discordance between the electronic medical record and self-report.
    Caverly LJ; Caverly TJ; Kalikin LM; Foster BK; Simon RH; LiPuma JJ
    J Cyst Fibros; 2016 Sep; 15(5):630-3. PubMed ID: 27156045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cystic fibrosis frequently asked questions.
    Lim SZ; Fitzgerald DA
    Paediatr Respir Rev; 2015 Mar; 16(2):110-1. PubMed ID: 25973462
    [No Abstract]   [Full Text] [Related]  

  • 60. Combination antibiotic susceptibility testing in cystic fibrosis.
    MacKenzie FM; Griffiths C; Dempsey O; Devereux G; Gould IM
    Lancet; 2005 Nov; 366(9498):1693; author reply 1693-4. PubMed ID: 16291059
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.